BRCA1 and ovarian carcinoma: The accelerated approval of olaparib by the FDA and EMA in patients with advanced BRCA1/2 mutation ovarian cancer (without specific platinum sensitivity status, FDA) heralded a new era in precision medicine in patients with advanced ovarian cancer.